Sionna Therapeutics, Inc. (NASDAQ:SION) Receives $45.43 Consensus Target Price from Brokerages

Sionna Therapeutics, Inc. (NASDAQ:SION) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $45.4286.

A number of brokerages recently weighed in on SION. Raymond James Financial restated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research report on Monday, January 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Royal Bank Of Canada reissued an “underperform” rating and set a $24.00 target price on shares of Sionna Therapeutics in a research report on Monday, December 1st. BTIG Research reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a research note on Wednesday, January 14th. Finally, Wall Street Zen raised shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th.

Insiders Place Their Bets

In other news, Director Orbimed Advisors Llc sold 33,356 shares of the business’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the transaction, the director directly owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. The trade was a 0.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Peter A. Thompson sold 33,356 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the sale, the director directly owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. This represents a 0.93% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 703,275 shares of company stock worth $29,467,911. Company insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

A number of large investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its holdings in shares of Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after purchasing an additional 529 shares during the period. BNP Paribas Financial Markets increased its position in Sionna Therapeutics by 35.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after buying an additional 619 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Sionna Therapeutics during the 4th quarter worth approximately $36,000. Russell Investments Group Ltd. bought a new position in Sionna Therapeutics in the third quarter worth approximately $30,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Sionna Therapeutics in the fourth quarter worth approximately $89,000.

Sionna Therapeutics Price Performance

NASDAQ SION opened at $43.65 on Friday. Sionna Therapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $45.00. The business has a fifty day moving average price of $41.44 and a two-hundred day moving average price of $32.55. The stock has a market capitalization of $1.95 billion and a PE ratio of -8.96.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.